NMD PHARMA NEUROMUSCULAR DISORDERS
Live / Registered — Cancelled — Section 71 (as of 06 Feb 2026)
What this means for you
Registered since 23 Jul 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79238525
- Registration number
- 5809155
- Mark type
- Design + words
- Filed
- 18 May 2018
- Published for opposition
- 07 May 2019
- Registered
- 23 Jul 2019
- Attorney of record
- Joel D. Leviton
Goods and services
- Class 005 — Pharmaceuticals: Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes [ and for research ] ; preparations for analysis for medical [ and research ] purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections
- Class 042 — Scientific and technological services: Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care
Owner
- NMD Pharma A/S, DK
- NMD Pharma A/S, DK
- NMD Pharma A/S, DK
Prosecution history
- 06 Feb 2026 — CANCELLED SECTION 71
- 23 Jul 2024 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 09 Sept 2023 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 03 Sept 2020 — INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
- 26 Jul 2020 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 06 Dec 2019 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Nov 2019 — CORRECTION UNDER SECTION 7 - PROCESSED
- 21 Nov 2019 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 14 Nov 2019 — FINAL DISPOSITION NOTICE SENT TO IB
- 14 Nov 2019 — LIMITATION FROM THE IB EXAMINED AND ENTERED
- 14 Nov 2019 — FINAL DISPOSITION PROCESSED
- 23 Oct 2019 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 23 Aug 2019 — LIMITATION OF GOODS RECEIVED FROM IB
- 23 Jul 2019 — REGISTERED-PRINCIPAL REGISTER
- 07 May 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED